Lih-Ching Hsu
Overview
Explore the profile of Lih-Ching Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang H, Kung F, Huang Y, Hsu C, Guh J, Hsu L
Biochem Pharmacol
. 2024 Mar;
223:116140.
PMID: 38513740
Cancer cells consume more glucose and usually overexpress glucose transporters which have become potential targets for the development of anticancer drugs. It has been demonstrated that selective SGLT2 inhibitors, such...
2.
Hsu J, Leu W, Hsu L, Hsieh C, Guh J
Oncol Lett
. 2024 Mar;
27(4):170.
PMID: 38455663
Lung cancer is the leading cause of cancer-related death worldwide, and ~85% of lung cancers are non-small cell lung cancer (NSCLC), which has a low 5-year overall survival rate and...
3.
Du C, Leu W, Jiang Y, Chan S, Chen I, Chang H, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2024 Mar;
397(9):6533-6550.
PMID: 38451282
The treatment of non-small cell lung cancer (NSCLC) is known as a significant level of unmet medical need in spite of the progress in targeted therapy and personalized therapy. Overexpression...
4.
Ye P, Leu W, Yeh T, Hsu Y, Lin Y, Wei Z, et al.
Prostate
. 2024 Feb;
84(6):605-619.
PMID: 38375594
Background: Metastatic castration-resistant prostate cancer (CRPC), the most refractory prostate cancer, inevitably progresses and becomes unresponsive to hormone therapy, revealing a pressing unmet need for this disease. Novel agents targeting...
5.
Chiang Y, Leu W, Chen Y, Ye P, Hsu Y, Hsiao Y, et al.
Prostate
. 2023 Aug;
83(16):1549-1563.
PMID: 37583103
Background: Castration-resistant prostate cancer (CRPC) is refractory to hormone treatment and the therapeutic options are continuously advancing. This study aims to discover the anti-CRPC effects and underlying mechanisms of small-molecule...
6.
Chiu P, Chang C, Huang P, Lin Y, Lin C, Yang H, et al.
J Med Chem
. 2023 Jul;
66(14):9684-9696.
PMID: 37413981
Irinotecan (), a prodrug of SN38 () approved by the US Food and Drug Administration for treating colorectal cancer, lacks specificity and causes many side effects. To increase the selectivity...
7.
Hsu Y, Kung F, Huang T, Deng Y, Guh J, Marchetti P, et al.
Molecules
. 2023 Mar;
28(5).
PMID: 36903603
Hepatocellular carcinoma is the third most common cause of cancer-related death according to the International Agency for Research on Cancer. Dihydroartemisinin (DHA), an antimalarial drug, has been reported to exhibit...
8.
Hung H, Li L, Guh J, Kung F, Hsu L
Molecules
. 2022 Nov;
27(22).
PMID: 36432207
Tumor cells rely on aerobic glycolysis to support growth and survival, thus require more glucose supply. Glucose transporters GLUTs, primarily GLUT1, are overexpressed in various cancers. Targeting GLUTs has been...
9.
Kao T, Wu H, Lee S, Liang P, Guh J, Hsu L
J Food Drug Anal
. 2022 Jun;
29(3):521-532.
PMID: 35696243
Glucose is an important energy source for cells. Glucose transport is mediated by two types of glucose transporters: the active sodium-coupled glucose cotransporters (SGLTs), and the passive glucose transporters (GLUTs)....
10.
Weng H, Sung C, Hsu J, Leu W, Guh J, Kung F, et al.
Front Pharmacol
. 2022 Jun;
13:879748.
PMID: 35662690
Breast cancer is the most prevalent cancer and the second leading cause of cancer death in women. Cisplatin is a commonly used chemotherapeutic drug for breast cancer treatment. Owing to...